併用療法 - AstraZeneca Activrag

Title:

併用療法

Document Type and Number:

Japanese Patent JP2009500384

Kind Code:

A

Abstract:

The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of AZD2171 in combination with gemcitabine; to a pharmaceutical composition comprising AZD2171 and gemcitabine; to a combination product comprising AZD2171 and gemcitabine for use in a method of treatment of a human or animal body by therapy; to a kit comprising AZD2171 and gemcitabine; to the use of AZD2171 and gemcitabine in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.

More Like This:

WO/2010/059953	QUINAZOLINE INHIBITORS OF BACE 1 AND METHODS OF USING
JP3071830	INDUSTRIAL APPLICABILITY Pyrimidine derivative as a 5HT2C receptor antagonist
WO/2016/198400	BENZOXAZINONE DERIVATIVES AND ANALOGUES THEREOF AS MODULATORS OF TNF ACTIVITY

Inventors:

Wedge, Stephen Robert

Application Number:

JP2008519988A

Publication Date:

January 08, 2009

Filing Date:

July 03, 2006

Export Citation:

Click for automatic bibliography generation Help

Assignee:

AstraZeneca Activrag

International Classes:

A61K31/517; A61K31/7064; A61P9/00; A61P35/00; A61P43/00

Other References:

JPN6012013479; Ｃａｎｃｅｒ　Ｒｅｓ．６５（１２）, 2005, ５３６５-７３
JPN6012013481; Ｊ　Ｃｌｉｎ　Ｏｎｃｏｌ．２２（５）, 2004, ７７７-８４
JPN6012013483; Ｐｒｏｃ　Ａｍ　Ａｓｓｏｃ　Ｃａｎｃｅｒ　Ｒｅｓ．４６, 2005
JPN6012013482; Ｃａｎｃｅｒ　Ｒｅｓ．６５（１０）, 2005, ４３８９-４００

Attorney, Agent or Firm:

Kazuo Shamoto
Shinjiro Ono
Yasushi Kobayashi
Akio Chiba
Hiroyuki Tomita
Ken Matsumoto

Previous Patent: 混合アルコールの脱水のための反応性蒸留

Next Patent: コア２ＧＬＣＮＡＣ−Ｔ阻害剤